"Lumigen's proprietary chemiluminescent chemistry is the detection method used in our Access® family of immunoassay systems," said Richard Creager, PhD, vice president of research and development for Beckman Coulter's immunoassay business. "Now, with Lumigen as part of the Beckman Coulter family, we are assured access to all of their current and future technology for immunochemical and other high-sensitivity testing."
Lumigen founder and president, Paul Schaap, PhD, said, "We have partnered with Beckman Coulter for more than 10 years and witnessed the significant growth of their immunoassay business. It is our goal continually to be at the forefront of detection technologies for clinical diagnostics and life science communities. Our current generation of products reflects this commitment and we look forward to the continued expansion of our business as we join with Beckman Coulter."
About 40 percent of Lumigen's 2005 revenues of $33 million were from sales of chemiluminescent substrate to Beckman Coulter for use in its immunoassay analyzers. Going forward, these related-party revenues will be eliminated in the consolidation. Lumigen also manufactures and licenses proprietary chemicals used by other clinical diagnostics and life-sciences manufacturers.
Beckman Coulter, Inc. is a leading manufacturer of biomedical testing instrument systems, reagents and supplies that simplify and automate laboratory processes. Spanning the biomedical testing continuum -- from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing -- Beckman Coulter's 200,000 installed systems provide essential biomedical information to enhance health care around the world. The company, based in Fullerton, California, reported 2005 annual sales of $2.44 billion, with 71.5 percent of this amount generated by recurring revenue from supplies, test kits, services and operating-type lease payments. For more information, visit www.beckmancoulter.com.
Contacts: Mary Luthy, Corporate Communications, Beckman Coulter Phone: (714) 993-8770 E-mail: mluthy@beckman.com Robert Raynor, Investor Relations, Beckman Coulter Phone: (714) 773-7620 E-mail: rraynor@beckman.com
Source: Beckman Coulter, Inc.
